Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $9.92, but opened at $9.33. Telix Pharmaceuticals shares last traded at $9.29, with a volume of 59,117 shares changing hands.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TLX shares. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. UBS Group lowered their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Citigroup started coverage on shares of Telix Pharmaceuticals in a research report on Thursday, September 18th. They set a “buy” rating and a $22.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Trading Down 5.7%

The business has a 50-day simple moving average of $10.03 and a 200-day simple moving average of $12.28.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Pier Capital LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $3,037,000. Portland Investment Counsel Inc. bought a new stake in Telix Pharmaceuticals in the 3rd quarter valued at $1,225,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals during the third quarter worth about $1,097,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.